Search results
SIGN guidelines are produced using a standard methodology that has been equality impact assessed to ensure that these equality aims are addressed in every guideline. This methodology is set out in the current version of SIGN 50, our guideline manual, which can
Quick Reference Guide. July 2017. Evidence. ESTIMATING CARDIOVASCULAR RISK. Individuals with the following risk factors should be considered at high risk of cardiovascular events: established cardiovascular disease, or. stage 3 or higher chronic kidney disease or micro- or macroalbuminuria, or. familial hypercholesterolaemia, or.
This guideline deals with the management of cardiovascular risk, both primary prevention, defined as the potential for intervention prior to the disease presenting through a specified event (any incident linked to critical disruption of blood flow that may cause damage to the heart, brain or peripheral tissues), and secondary prevention ...
30 sie 2024 · This 2024 guideline, developed by a multidisciplinary Task Force, updates the 2018 ESC/ESH guidelines on the management of arterial hypertension, using the most robust contemporary evidence.
28 sie 2019 · This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
The 2020 ISH Global Hypertension Practice Guidelines were developed by the ISH Hypertension Guidelines Committee based on evidence criteria, (1) to be used globally; (2) to be fit for application in low and high resource settings by advis-ing on essential and optimal standards; and (3) to be concise, simplified, and easy to use.
30 sie 2024 · For patients with elevated BP and borderline increased predicted CVD risk by SCORE2/SCORE2-OP (5% to <10% over 10 years), up-classification of risk may be considered in the presence of sex-specific or shared non-traditional risk modifiers.
